A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Topiramate, a novel anticonvulsant, has been reported to rapidly reduce symptoms of posttraumatic stress disorder (PTSD) in an open-label trial. The present study was designed as a test of topiramate's efficacy as adjunctive therapy in a 7-week, randomized, double-blind, placebo-controlled trial. METHODS: Forty male veterans with PTSD in a residential treatment program were randomized to flexible-dose topiramate or placebo augmentation. The primary outcome measures were PTSD symptom severity and global symptom improvement. RESULTS: Baseline Clinician-Administered PTSD Scale scores were 62.1 +/- 13.9 for placebo and 61.0 +/- 22.2 for topiramate. There was a high dropout rate from the study (55% topiramate; 25% placebo), with 40% of topiramate and 10% of placebo dropping because of adverse events (AEs). No significant treatment effects of topiramate versus placebo were observed for the primary treatment outcomes. Subjects reporting central nervous system-related AEs and with higher baseline severity of depression were more likely to discontinue because of AEs. CONCLUSIONS: Primary outcome measures failed to demonstrate a significant effect for topiramate over placebo; however, high dropout rate in the treatment group prohibits definitive conclusions about the efficacy of topiramate in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trauma and Posttraumatic Stress Disorder in the Community: The 1996 Detroit Area Survey of Trauma
Breslau, N., Kessler, R. C., Chilcoat, H. D., Schultz, L. R., Davis, G. C., & Andreski, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.626 · Cited by 2,407
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519 · cited 2×
“A recent meta-analysis showed evidence for treatment efficacy for PTSD of several classes of medication, including selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants, but less reduction in symptom severity was observed in treatment trials composed primarily of US Vietn…”
BackgroundMethod
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Rytwinski, N. K., Scur, M. D., Feeny, N. C., & Youngstrom, E. A. (2013) · Journal of Traumatic Stress · doi:10.1002/jts.21814 · Cited by 669
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits
Ressler, K. J., Berretta, S., Bolshakov, V. Y., Rosso, I. M., Meloni, E. G., Rauch, S. L., & Carlezon, W. A. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00635-8 · Cited by 481
Coventry, P. A., Meader, N., Melton, H., Temple, M., Dale, H., Wright, K., Cloitre, M., Karatzias, T., Bisson, J., Roberts, N. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003262 · Cited by 358
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Metadata
- Authors
- Lindley, S. E., Carlson, E. B., & Hill, K.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 677-681
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2091257758
- Cited by
- 77
- References
- 2
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e31815a43ee
- The paper
- Lindley, S. E., Carlson, E. B., & Hill, K. (2007). A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31815a43ee
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.